Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Aptose Bioscns
(NQ:
APTO
)
0.1842
-0.0058 (-3.05%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 25, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Aptose Bioscns
< Previous
1
2
3
4
5
Next >
Why Inovio Pharmaceuticals Shares Are Trading Higher By 12%; Here Are 20 Stocks Moving Premarket
May 24, 2023
Gainers Minerva Surgical, Inc. (NASDAQ: UTRS) shares rose 202.3% to $0.5499 in pre-market trading. Minerva Surgical was granted U.S. Patent #11653972 for "Medical Systems And Methods (For Resecting And...
Via
Benzinga
Aptose Biosciences Announces Results of Annual and Special Meeting of Shareholders
May 23, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
3 Stocks With 1,000% Upside Potential
May 21, 2023
If you're an investor comfortable with speculative bets, analysts are price targeting these stocks with 1000% upside.
Via
InvestorPlace
Analyst Expectations for Aptose Biosciences's Future
May 09, 2023
Via
Benzinga
Canaccord Genuity Maintains Buy Rating for Aptose Biosciences: Here's What You Need To Know
March 27, 2023
Via
Benzinga
Preview: Aptose Biosciences's Earnings
March 22, 2023
Via
Benzinga
Stocks That Hit 52-Week Lows On Thursday
October 20, 2022
Thursday saw 177 companies set new 52-week lows.
Via
Benzinga
Aptose Reports Results for the First Quarter 2023
May 08, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose to Participate in RBC Capital Markets 2023 Global Healthcare Conference
May 04, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose to Report First Quarter 2023 Financial Results and Hold Conference Call on Monday, May 8, 2023
April 24, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose to Participate in Canaccord Genuity’s 2023 Horizons in Oncology Virtual Conference
April 10, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Biosciences to Participate in Cantor’s The Future of Oncology Virtual Symposium
March 28, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Reports Results for the Fourth Quarter and Full Year 2022
March 23, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Earnings Scheduled For March 23, 2023
March 23, 2023
Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is likely to report earnings for its fourth quarter.
Via
Benzinga
Aptose Reports Immaterial Financial Exposure to Silicon Valley Bank
March 10, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose to Report Fourth Quarter and Full Year 2022 Financial Results and Hold Conference Call on Thursday, March 23, 2023
March 09, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Biosciences to Present at Oppenheimer 33rd Annual Healthcare Conference
March 02, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
February 13, 2023
It's time to start the week with a breakdown of the biggest pre-market stock movers traders will want to keep a watch on Monday!
Via
InvestorPlace
Aptose Initiates Dosing of Tuspetinib in APTIVATE Expansion Trial in Patients with Acute Myeloid Leukemia
January 30, 2023
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Biosciences to Present at Biotech Showcase™ 2023 Conference
December 28, 2022
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Why Aptevo Therapeutics Shares Are Trading Higher By More Than 100%; Here Are 28 Stocks Moving Premarket
December 12, 2022
Gainers
Via
Benzinga
Aptose Biosciences Establishes New At-The-Market Facility
December 12, 2022
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Announces Updated Clinical Responses, Breadth of Activity, and Safety Across Four Dose Levels of Tuspetinib in Difficult-to-Treat Acute Myeloid Leukemia Populations
December 11, 2022
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose to Hold Clinical Update and Data Review of AML Drug Tuspetinib on Sunday, December 11th
December 07, 2022
Data to be presented in poster at ASH Annual Meeting
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Treats First Patient with Continuous Dosing of New “G3” Formulation of Luxeptinib
November 14, 2022
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Why Lincoln National Shares Are Trading Lower By 31%? Here Are 72 Stocks Moving In Thursday's Session
November 03, 2022
Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) gained 64% to $50.60.
Via
Benzinga
Why Greenhill Shares Climbed Around 25%; Here Are 100 Biggest Movers From Yesterday
November 04, 2022
Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) shares jumped 242.8% to close at $105.72 on Thursday. The company announced a strategic plan to enter into the clean energy industry.
Via
Benzinga
Aptose Clinical Data to be Presented at the 2022 ASH Annual Meeting
November 03, 2022
Data for Tuspetinib (HM43239) and Luxeptinib Accepted for Poster Presentation
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Aptose Reports Results for the Third Quarter 2022
November 01, 2022
From
Aptose Biosciences, Inc.
Via
GlobeNewswire
Stocks That Hit 52-Week Lows On Tuesday
October 25, 2022
On Tuesday, 120 companies set new 52-week lows.
Via
Benzinga
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.